INTENSITY THERAPEUTICS RSS Feed | Nachrichten - www.finanzen.net

Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium

Thu, 11 Dec 2025 13:47:00 +0100

Poster PS5-08-16 Reports Early Observations from the INVINCIBLE-4 Study, an Ongoing Randomized, Presurgical Phase 2 Clinical Trial for Triple Negative Breast Cancer continue to show favorable ...

Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Fri, 05 Dec 2025 13:30:00 +0100

SHELTON, Conn., Dec. 5, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") ...

Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium

Thu, 04 Dec 2025 13:47:00 +0100

SHELTON, Conn., Dec. 4, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" ...

Intensity Therapeutics veröffentlichte Zahlen zum vergangenen Quartal

Sun, 09 Nov 2025 06:35:07 +0100

Intensity Therapeutics hat am 06.11.2025 die Bücher zum am 30.09.2025 abgelaufenen Quartal geöffnet.Das EPS lag bei -0,06 USD. Ein Jahr zuvor waren -0,250 USD je Aktie erzielt worden.Redaktion finanz ...

Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Thu, 06 Nov 2025 22:02:00 +0100

The Company expects to file a protocol amendment in the INVINCIBLE-4 Study to revise the dosing regimen for the INT230-6 treatment cohort, and to reinitiate patient enrollment in the first quarter ...

Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal

Thu, 30 Oct 2025 12:30:00 +0100

The paper features a comprehensive evaluation of data, including disease control rate, overall survival, immune activation, abscopal effects, tumor necrosis, dose ranging, and safety